Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (11-20 of 255) with videos related to

Pageof 26
Sort By:
Clinical Nuclear Medicine|November 12, 2013
Targeted α-particle therapy of bone metastases in prostate cancerHossein Jadvar, David I Quinn
Drug Safety|June 1, 1995
Drug interactions of clinical importance. An updated guideD I Quinn, R O Day
Cancer|August 1, 2009
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor?Tanya B Dorff, David I Quinn
The New England Journal of Medicine|September 26, 2015
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple KinasesDavid I Quinn, Primo N Lara
Cancer Treatment Reviews|February 26, 2013
Differentiating mTOR inhibitors in renal cell carcinomaSumanta K Pal, David I Quinn
Journal of Research of the National Bureau of Standards. Section A, Physics and Chemistry|March 21, 2020
Mass Spectra of Some DeuteroethanesEdith I Quinn, Fred L Mohler
Clinical Genitourinary Cancer|January 24, 2006
Cytokine therapy: a standard of care for metastatic renal cell carcinoma?Thomas E Hutson, David I Quinn
Otolaryngologic Clinics of North America|April 4, 2006
Dental considerations in the management of head and neck cancer patientsEric H Miller, Aubrey I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2013
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minusT B Dorff, D I Quinn
Lancet (London, England)|October 5, 2010
Cabazitaxel in prostate cancer: stretching a stringTanya B Dorff, David I Quinn
Pageof 26

Showing results (11-20 of 255) with videos related to

Sort By:
Pageof 26
Clinical Nuclear Medicine|November 12, 2013
Targeted α-particle therapy of bone metastases in prostate cancerHossein Jadvar, David I Quinn
Drug Safety|June 1, 1995
Drug interactions of clinical importance. An updated guideD I Quinn, R O Day
Cancer|August 1, 2009
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor?Tanya B Dorff, David I Quinn
The New England Journal of Medicine|September 26, 2015
Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple KinasesDavid I Quinn, Primo N Lara
Cancer Treatment Reviews|February 26, 2013
Differentiating mTOR inhibitors in renal cell carcinomaSumanta K Pal, David I Quinn
Journal of Research of the National Bureau of Standards. Section A, Physics and Chemistry|March 21, 2020
Mass Spectra of Some DeuteroethanesEdith I Quinn, Fred L Mohler
Clinical Genitourinary Cancer|January 24, 2006
Cytokine therapy: a standard of care for metastatic renal cell carcinoma?Thomas E Hutson, David I Quinn
Otolaryngologic Clinics of North America|April 4, 2006
Dental considerations in the management of head and neck cancer patientsEric H Miller, Aubrey I Quinn
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2013
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minusT B Dorff, D I Quinn
Lancet (London, England)|October 5, 2010
Cabazitaxel in prostate cancer: stretching a stringTanya B Dorff, David I Quinn
Pageof 26